← Back to Pipeline Dashboard Open Source Medicine Foundation

Pneumococcal Vaccine

Phase 3 Clinical Trial

Developer: University of Sao Paulo General Hospital  |  Target Disease: Autoimmune Rheumatologic Disease

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Autoimmune Rheumatologic Disease Vaccine Guide →
Development Phase Phase 3 Clinical Trial Primary Status
Platform Technology Biological (unspecified platform) Biologic Architecture
Target Indication Autoimmune Rheumatologic Disease Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture
Biological (unspecified platform)
Lead Developer
University of Sao Paulo General Hospital
Next Expected Milestone
Primary completion (most advanced trial): 2026-12-30 (registry estimate)
Analyst & Development Notes
Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT07252791 →
Additional Sources & Literature

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT07252791 Phase 3 Clinical Trial

Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases

Status: Active / Ongoing • Expected Readout: 2026-12-30
NCT07242092 Phase 3 Clinical Trial

Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs

Status: Active / Ongoing • Expected Readout: 2027-12-30

Milestone Overview

  • Stage Verification
    Phase 3 Clinical Trial confirmed as of 2026-07-10.
  • Target Milestone
    Primary completion (most advanced trial): 2026-12-30 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.